Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026 ...Middle East

NOVATO, Calif., July 13, 2026 /PRNewswire/ -- Lighthouse Pharmaceuticals today announced new analyses from the Phase 2/3 GAIN trial demonstrating that atuzaginstat, a gingipain inhibitor targeting Porphyromonas gingivalis (Pg), was associated with benefits in several neuropsychiatric...

Hence then, the article about lighthouse pharmaceuticals reports new evidence that gingipain inhibition benefits neuropsychiatric symptoms and reduces caregiver distress in p gingivalis positive alzheimer s disease at aaic 2026 was published today ( Monday 13/07/2026 - 11:07 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026 )

Also on site :

• One Minnesota Vikings Rookie Who Could Win a Starting Job Out of Camp
• Paramount Reportedly Considering Leaving California as State Readies Lawsuit Over Warner Bros. Discovery Merger
• Nordstrom Rack’s $27 Pearl Necklace and Bracelet Set Is an ‘Elegant’ Way to Nail the Coastal-Chic Aesthetic